Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in Northwest Spain

Journal of Rheumatology

Volumn 33, Issue 2, 2006, Pages 285-288

  Martin, Javier ^a   Perez Armengol, Cristina ^a   Miranda Filloy, Jose A ^c   Vilchez, Jose R ^b   Lopez Nevot, Miguel A ^b   Garcia Porrua, Carlos ^c   Gonzalez Gay, Miguel A ^c  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

Author keywords

94ins delATTG NFKB1 promoter; Giant cell (temporal) arteritis; Polymorphism; Severe ischemic manifestations; Susceptibility

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOPSY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENOTYPE; GIANT CELL ARTERITIS; HUMAN; IMMUNE RESPONSE; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RHEUMATIC POLYMYALGIA; SPAIN;

AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, GENETIC; POLYMYALGIA RHEUMATICA; SPAIN; TEMPORAL ARTERITIS;

EID: 32144437398     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 2001;27:729-49.
2. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
3. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48.
4. Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation. Immunol Rev 2005;203:21-37.
5. Baeuerle PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988;53:211-7.
6. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242:540-6.
7. Firestein GS. NF-kappaB: Holy Grail for rheumatoid arthritis? Arthritis Rheum 2004;50:2381-6.
8. Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997;40:19-26.
9. Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997;40:19-26.
10. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 2004;3:46-53.
11. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997;99:2842-50.
12. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002;46:457-66.
13. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45.
14. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
15. Gonzalez-Gay MA, Piñeiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine Baltimore 2004;83:342-7.
16. Baldwin AS Jr. Series introduction: The transcription factor NF-kappaB and human disease. J Clin Invest 2001;107:3-6.
17. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
18. Orozco G, Sanchez E, Collado MD, et al. Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2005;65:183-6.
19. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
20. Tak PP, Firestein GS. NF-kB: a key role on inflammatory diseases. J Clin Invest 2001;107:7-11.
21. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-34.